Results 91 to 100 of about 12,515 (211)

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Drug Design, Development and Therapy, 2017
Ali Kadivar,1 Behnam Kamalidehghan,1 Hamid Akbari Javar,2 Benyamin Karimi,3 Reihaneh Sedghi,4 Mohamed Ibrahim Noordin1 1Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2Department of Pharmaceutics, Faculty of ...
Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R, MI Noordin   +5 more
doaj  

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia [PDF]

, 2002
James C. Barton, S. Christopher Jones, Wade C. Lamberth, Michael T. Reymann, Varian C. Scott   +4 more
openalex   +1 more source

The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. [PDF]

PLoS Pathog, 2023
Cleverley TL, Peddineni S, Guarner J, Cingolani F, Garcia PK, Koehler H, Mocarski ES, Kalman D.   +7 more
europepmc   +1 more source

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Brazilian Journal of Pharmaceutical Sciences
Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic ...
Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres   +4 more
doaj   +1 more source

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia [PDF]

, 2002
Hendrik W. van Deventer, Melissa D. Hall, Robert Z. Orlowski, Beverly S. Mitchell, Lee R. Berkowitz, Cathe Hogan, Cherie H. Dunphy, Julie Koehler, Thomas C. Shea   +8 more
openalex   +1 more source

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]

Iran J Basic Med Sci, 2023
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S.   +3 more
europepmc   +1 more source

Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy [PDF]

, 2002
Stuart L. Goldberg, Ravi A. Madan, Scott D. Rowley, Andrew L. Pecora, Jack W. Hsu, Ramana Tantravahi   +5 more
openalex   +1 more source

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Ida‐FLAG plus imatinib mesylate‐induced molecular remission in a patient with chemoresistant Ph¹(+) acute myeloid leukemia [PDF]

, 2003
Nora‐Athina Viniou, Theodoros P. Vassilakopoulos, Xanthi Giakoumi, Marina Mantzouranis, Gerassimos A. Pangalis   +4 more
openalex   +1 more source

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. [PDF]

PLoS One, 2022
PLOS ONE Editors.
europepmc   +1 more source